It was suggested that KS-133 NPs enhanced the pharmacological efficacy of the anti-PD-1 antibody because the tumor volume of the anti-PD-1 antibody group was 50% (Fig 2A) and that of the KS-133 NP (q3d) group was 38% (Fig 2B). This evidence concerns the gene PDCD1 and neoplasm.